MarketCap
Facebook
X
Telegram
Akebia Therapeutics Cash and Cash Equivalents | AKBA
Annual Cash and Cash Equivalents Akebia Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 185 M | 51.9 M | 42.9 M | 90.5 M | 150 M | 229 M | 147 M | 105 M | 70.2 M | 187 M | 49.8 M | 32.8 M | 21.2 M | 1.64 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 229 M | 1.64 M | 97.4 M |
Quarterly Cash and Cash Equivalents Akebia Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 156 M | 163 M | 166 M | 137 M | 113 M | 51.9 M | 35.7 M | 41.2 M | 43.6 M | 42.9 M | 48.2 M | 55.3 M | 57 M | 90.5 M | 148 M | 147 M | 178 M | 150 M | 209 M | 247 M | 253 M | 229 M | 229 M | 229 M | 229 M | 147 M | 147 M | 147 M | 147 M | 105 M | 105 M | 105 M | 105 M | 70.2 M | 70.2 M | 70.2 M | 70.2 M | 187 M | 187 M | 187 M | 187 M | 49.8 M | 49.8 M | 49.8 M | 49.8 M | 32.8 M | 32.8 M | 32.8 M | 32.8 M | 21.2 M | 21.2 M | 21.2 M | 21.2 M | 1.64 M | - | - | - | 5.01 M | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 253 M | 1.64 M | 107 M |
Cash and Cash Equivalents of other stocks in the Biotechnology industry
| Issuer | Cash and Cash Equivalents | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MEI Pharma
MEIP
|
5.71 M | - | 10.43 % | $ 20.5 M |  USA |
 |
Palatin Technologies
PTN
|
7.49 M | - | - | $ 13 M | USA |
 |
Lyra Therapeutics
LYRA
|
15.9 M | - | - | $ 24.9 M | USA |
 |
Ionis Pharmaceuticals
IONS
|
372 M | $ 43.5 | 0.62 % | $ 6.96 B | USA |
 |
Agios Pharmaceuticals
AGIO
|
89.1 M | $ 31.25 | 0.88 % | $ 1.81 B | USA |
 |
Foghorn Therapeutics
FHTX
|
80.9 M | $ 2.0 | 0.74 % | $ 126 M | USA |
 |
Inhibikase Therapeutics
IKT
|
179 M | $ 2.0 | 0.5 % | $ 197 M | USA |
 |
Kamada Ltd.
KMDA
|
75.5 M | $ 8.0 | 1.34 % | $ 461 M |  Israel |
 |
Intellia Therapeutics
NTLA
|
155 M | $ 12.75 | 4.0 % | $ 1.38 B | USA |
 |
Ultragenyx Pharmaceutical
RARE
|
421 M | $ 14.5 | 3.19 % | $ 1.43 B | USA |
 |
Viridian Therapeutics
VRDN
|
212 M | $ 19.0 | 2.16 % | $ 1.93 B | USA |
 |
AbbVie
ABBV
|
5.23 B | $ 265.76 | 1.12 % | $ 470 B | USA |
 |
AbCellera Biologics
ABCL
|
129 M | $ 13.78 | 0.29 % | $ 4.12 B |  Canada |
 |
Abeona Therapeutics
ABEO
|
78.4 M | $ 5.11 | 1.59 % | $ 271 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
18 M | $ 4.67 | 4.94 % | $ 895 M | Canada |
 |
ACADIA Pharmaceuticals
ACAD
|
178 M | $ 20.11 | 0.8 % | $ 3.39 B | USA |
 |
Achieve Life Sciences
ACHV
|
20.9 M | $ 7.01 | 0.13 % | $ 306 M | USA |
 |
AC Immune SA
ACIU
|
26.8 M | $ 2.71 | 0.55 % | $ 273 M |  Schweiz |
 |
Aclaris Therapeutics
ACRS
|
20 M | $ 4.27 | 0.79 % | $ 523 M | USA |
 |
Adagene
ADAG
|
74.5 M | $ 2.8 | 0.28 % | $ 165 M |  China |
 |
ADC Therapeutics SA
ADCT
|
261 M | $ 1.23 | 8.85 % | $ 156 M | Schweiz |
 |
Adial Pharmaceuticals
ADIL
|
5.88 M | $ 4.35 | 5.58 % | $ 2.91 M | USA |
 |
ADMA Biologics
ADMA
|
87.6 M | $ 10.11 | 4.01 % | $ 2.41 B | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
70.5 M | $ 29.84 | 5.26 % | $ 4.53 B | USA |
 |
Agenus
AGEN
|
3 M | $ 8.73 | 4.43 % | $ 260 M | USA |
 |
AIM ImmunoTech
AIM
|
2.98 M | $ 0.19 | 5.56 % | $ 308 K | USA |
 |
Akari Therapeutics, Plc
AKTX
|
2.6 M | $ 8.76 | 0.46 % | $ 590 B |  Britain |
 |
Aldeyra Therapeutics
ALDX
|
70 M | $ 0.92 | 4.88 % | $ 55.3 M | USA |
 |
Alector
ALEC
|
65.8 M | $ 1.99 | 9.94 % | $ 205 M | USA |
 |
Aligos Therapeutics
ALGS
|
18.3 M | $ 5.4 | 0.36 % | $ 53.4 M | USA |
 |
Alkermes plc
ALKS
|
389 M | $ 42.76 | 2.42 % | $ 7.04 B |  Irlanda |
 |
Allogene Therapeutics
ALLO
|
51.7 M | $ 1.5 | 0.33 % | $ 331 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
1.66 B | $ 219.89 | 0.08 % | $ 28.8 B | USA |
 |
Altimmune
ALT
|
43.8 M | $ 2.67 | 0.36 % | $ 235 M | USA |
 |
ALX Oncology Holdings
ALXO
|
16.4 M | $ 1.21 | 1.23 % | $ 64.9 M | USA |
 |
Amgen
AMGN
|
9.13 B | $ 402.98 | 0.08 % | $ 217 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
170 M | $ 25.37 | 0.39 % | $ 1.19 B | USA |
 |
Amarin Corporation plc
AMRN
|
135 M | $ 12.09 | 0.31 % | $ 5.02 B | Irlanda |
 |
Amneal Pharmaceuticals
AMRX
|
282 M | $ 20.35 | 0.25 % | $ 6.38 B | USA |
 |
AnaptysBio
ANAB
|
134 M | $ 49.2 | 1.38 % | $ 1.43 B | USA |
 |
Anika Therapeutics
ANIK
|
57.5 M | $ 19.73 | 3.3 % | $ 283 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
286 M | $ 72.58 | 0.55 % | $ 1.46 B | USA |
 |
Annexon
ANNX
|
162 M | $ 4.2 | 0.24 % | $ 651 M | USA |